Table 2.

Merits and demerits of treating systemic mycoses with therapeutic monoclonal antibodies (140).

Merits	Demerits
MAbs offer fast protection from the pathogenic microorganisms that cause systemic mycosis.	Since MAbs are extremely specific, they should only be utilized after an accurate agent identification.
By increasing the efficiency of antifungal drugs, MAbs can shorten the time needed for treatment (Synergistic drug approach).	As the infection worsens, the effectiveness of MAbs may be completely devastated.
Since MAbs are specially designed to target pathogen epitopes, they do not pose a cytotoxicity concern.	MAbs cost substantially more to manufacture compared to antimycotic agents.
The microbiota is not altered by MAbs.	MAbs are more challenging to administrate and maintain than traditional antifungal treatments.
There is a large variety of molecular epitopes against which MAbs can be initially produced.